Feedback / Questions
gusacitinib (ASN002) - Sanofi
https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html
Jun 23, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next